HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of $4.16 per share for the year, up from their previous estimate of $3.98. HC Wainwright currently has a “Buy” rating and a $87.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2029 earnings at $6.29 EPS.

A number of other research firms also recently commented on DNLI. William Blair assumed coverage on Denali Therapeutics in a report on Friday, January 3rd. They set an “outperform” rating on the stock. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. JPMorgan Chase & Co. lowered their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Monday, December 16th. Finally, Cantor Fitzgerald downgraded shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $21.25 on Wednesday. The firm has a fifty day moving average of $24.23 and a two-hundred day moving average of $24.86. The firm has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) earnings per share.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now directly owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This represents a 6.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,518 shares of company stock valued at $2,576,982. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in shares of Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after purchasing an additional 14,324 shares during the period. Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after buying an additional 149,939 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Denali Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock worth $2,148,000 after buying an additional 2,901 shares during the period. Barclays PLC increased its position in shares of Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company’s stock worth $7,454,000 after acquiring an additional 128,823 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics during the third quarter valued at approximately $1,894,000. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.